FDA Clears Iovance’s IOV-5001 Phase 1/2 Trial in Cancers Causing 100,000+ Annual Deaths
IOVA•Iovance Biotherapeutics received FDA clearance to initiate a Phase 1/2 basket trial of IOV-5001, an IL-12 tethered TIL therapy, in the second half of 2026 across cohorts including advanced colorectal, triple-negative and ER-low breast cancers that account for over 100,000 U.S. deaths annually. IOV-5001 is engineered to anchor IL-12 on the TIL surface to enhance efficacy and safety, enabling higher cell doses and building on a prior IL-12 TIL therapy that achieved a 63% objective response rate.
1. IND Clearance and Trial Design
Iovance secured FDA allowance to proceed with an IND application for IOV-5001, authorizing a Phase 1/2 basket trial beginning in the second half of 2026. The one-time treatment regimen will investigate safety and efficacy without IL-2 across advanced colorectal, triple-negative and ER-low breast cancer cohorts, among other solid tumors.
2. IOV-5001 Mechanism and Advantages
IOV-5001’s design tethers IL-12 to the TIL cell surface, restricting cytokine activity to the tumor microenvironment to optimize safety and reduce systemic exposure. This approach supports administration of higher cell doses and aims to activate immunologically cold tumors more effectively than unmodified TIL therapies.
3. Preclinical and Clinical Background
Preclinical studies demonstrated stronger antitumor activity and a more durable T cell profile compared to unmodified TILs. The therapy builds on an earlier IL-12 TIL candidate that delivered a 63% confirmed objective response rate, highlighting potential for improved outcomes in solid tumors.
4. Strategic Implications and Market Potential
By targeting cancers responsible for over 100,000 U.S. deaths annually, Iovance extends its commercial TIL platform into new indications. Successful Phase 1/2 results could position IOV-5001 as a next-generation cell therapy, expanding market opportunity and supporting long-term pipeline value.
